Astal Laboratories
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Astal Laboratories’ promoter, Aceso Research Labs LLP, bought 25,417 equity shares on the BSE between 24 August and 8 September 2026 for ₹19,99,812, taking its holding from 19,85,595 to 20,11,012 shares. The open-market purchase was reported to the company on 10 September. Aceso had also bought 21,007 shares in March, when its holding was around 4.7% of the company. Astal reported standalone FY26 operating revenue of about ₹156 crore and consolidated operating revenue of about ₹249 crore, including roughly two and a half months of its API subsidiary’s results.
Powered by Tijori
Astal Laboratories’ promoter, Aceso Research Labs LLP, bought 25,417 equity shares on the BSE between 24 August and 8 September 2026 for ₹19,99,812, taking its holding from 19,85,595 to 20,11,012 shares. The open-market purchase was reported to the company on 10 September. Aceso had also bought 21,007 shares in March, when its holding was around 4.7% of the company. Astal reported standalone FY26 operating revenue of about ₹156 crore and consolidated operating revenue of about ₹249 crore, including roughly two and a half months of its API subsidiary’s results.
Powered by Tijori
Aug 14 (Reuters) - Astal Laboratories Ltd ASTB.BO:
JUNE-QUARTER CONSOL PROFIT 94.2 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.01 BILLION RUPEES
Source text:
Further company coverage: ASTB.BO
(([email protected];))
Aug 14 (Reuters) - Astal Laboratories Ltd ASTB.BO:
JUNE-QUARTER CONSOL PROFIT 94.2 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.01 BILLION RUPEES
Source text:
Further company coverage: ASTB.BO
(([email protected];))
Astal Laboratories Limited on Monday authorised its whole‑time director to initiate talks for acquiring USFDA, EU‑GMP or WHO‑GMP compliant pharmaceutical manufacturing units in India. The board also empowered the chief financial officer to engage with prospective investors for raising up to ₹300 crore through convertible and non‑convertible instruments via private placement. The decisions were taken to expand manufacturing capacity, meet rising order volumes, and strengthen the company’s presence in global markets. The fundraise would be subject to statutory and shareholder approvals.
Powered by Tijori
Astal Laboratories Limited on Monday authorised its whole‑time director to initiate talks for acquiring USFDA, EU‑GMP or WHO‑GMP compliant pharmaceutical manufacturing units in India. The board also empowered the chief financial officer to engage with prospective investors for raising up to ₹300 crore through convertible and non‑convertible instruments via private placement. The decisions were taken to expand manufacturing capacity, meet rising order volumes, and strengthen the company’s presence in global markets. The fundraise would be subject to statutory and shareholder approvals.
Powered by Tijori
Dec 29 (Reuters) - Astal Laboratories Ltd ASTB.BO:
SIGNED LETTER OF INTENT WITH IMMUNA THERAPEUTICS GMBH
COLLABORATION INCLUDES TECHNOLOGY TRANSFER AND LOCALIZATION IN INDIA
IMMUNA COLLABORATION EXPECTED TO GENERATE 3 BILLION RUPEES REVENUE
Source text: ID:nBSE7LXxl5
Further company coverage: ASTB.BO
(([email protected];))
Dec 29 (Reuters) - Astal Laboratories Ltd ASTB.BO:
SIGNED LETTER OF INTENT WITH IMMUNA THERAPEUTICS GMBH
COLLABORATION INCLUDES TECHNOLOGY TRANSFER AND LOCALIZATION IN INDIA
IMMUNA COLLABORATION EXPECTED TO GENERATE 3 BILLION RUPEES REVENUE
Source text: ID:nBSE7LXxl5
Further company coverage: ASTB.BO
(([email protected];))
Oct 10 (Reuters) - Astal Laboratories Ltd ASTB.BO:
ASTAL LABORATORIES LTD - TO BUY 100% OF SRIVEN PHARMACHEM
ASTAL LABORATORIES LTD - ACQUISITION COST SET AT 2.77 BILLION RUPEES
Source text: ID:nBSE5qss1z
Further company coverage: ASTB.BO
(([email protected];;))
Oct 10 (Reuters) - Astal Laboratories Ltd ASTB.BO:
ASTAL LABORATORIES LTD - TO BUY 100% OF SRIVEN PHARMACHEM
ASTAL LABORATORIES LTD - ACQUISITION COST SET AT 2.77 BILLION RUPEES
Source text: ID:nBSE5qss1z
Further company coverage: ASTB.BO
(([email protected];;))
Oct 16 (Reuters) - Astal Laboratories Ltd ASTB.BO:
BUYS PHARMACEUTICAL INTERMEDIATES MANUFACTURING PLANT OF SHREE VENUS HEALTH SCIENCES
ACQUISITION FOR 96 MILLION RUPEES
Source text for Eikon: ID:nBSE8jmNVm
Further company coverage: ASTB.BO
(([email protected];;))
Oct 16 (Reuters) - Astal Laboratories Ltd ASTB.BO:
BUYS PHARMACEUTICAL INTERMEDIATES MANUFACTURING PLANT OF SHREE VENUS HEALTH SCIENCES
ACQUISITION FOR 96 MILLION RUPEES
Source text for Eikon: ID:nBSE8jmNVm
Further company coverage: ASTB.BO
(([email protected];;))
Dec 20 (Reuters) - Macro International Ltd MACR.BO:
APPROVED RAISING OF FUNDS
TO ISSUE 4.9 MILLION SHARES AT ISSUE PRICE OF 30 RUPEES EACH
Source text for Eikon: ID:nBSE3hdVHw
Further company coverage: MACR.BO
(([email protected];))
Dec 20 (Reuters) - Macro International Ltd MACR.BO:
APPROVED RAISING OF FUNDS
TO ISSUE 4.9 MILLION SHARES AT ISSUE PRICE OF 30 RUPEES EACH
Source text for Eikon: ID:nBSE3hdVHw
Further company coverage: MACR.BO
(([email protected];))
Dec 15 (Reuters) - Macro International Ltd MACR.BO:
TO CONSIDER ISSUE OF SHARES ON PREFERENTIAL BASIS
Further company coverage: MACR.BO
(([email protected];))
Dec 15 (Reuters) - Macro International Ltd MACR.BO:
TO CONSIDER ISSUE OF SHARES ON PREFERENTIAL BASIS
Further company coverage: MACR.BO
(([email protected];))
Aug 24 (Reuters) - Macro International Ltd MACR.BO:
VENTURES INTO CONTRAST MEDIA BUSINESS, INTRODUCES LOPROMIDE USP FOR BULK DRUG MANUFACTURING
Source text for Eikon: ID:nBSE70y44l
Further company coverage: MACR.BO
(([email protected];))
Aug 24 (Reuters) - Macro International Ltd MACR.BO:
VENTURES INTO CONTRAST MEDIA BUSINESS, INTRODUCES LOPROMIDE USP FOR BULK DRUG MANUFACTURING
Source text for Eikon: ID:nBSE70y44l
Further company coverage: MACR.BO
(([email protected];))
June 19 (Reuters) - Macro International Ltd MACR.BO:
SESHA SAI NIKHIL CHINTALAPATI RESIGNS AS CHIEF FINANCIAL OFFICER
Source text for Eikon: ID:nBSE5shqp
Further company coverage: MACR.BO
(([email protected];))
June 19 (Reuters) - Macro International Ltd MACR.BO:
SESHA SAI NIKHIL CHINTALAPATI RESIGNS AS CHIEF FINANCIAL OFFICER
Source text for Eikon: ID:nBSE5shqp
Further company coverage: MACR.BO
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Astal Laboratories do?
Macro International Ltd, incorporated in 1993, is a company engaged in exporting goods such as bridles, halters, rugs, saddles, strip leather, reins, shoes, and bell boots, along with sales via departmental stores.
Who are the competitors of Astal Laboratories?
Astal Laboratories major competitors are Evexia Lifecare, QMS Medi Allied Ser., Pipan Oils, Vega Jewellers, Dynamic Services, HCL Infosystems, Silkflex Polymers(I). Market Cap of Astal Laboratories is ₹321 Crs. While the median market cap of its peers are ₹325 Crs.
Is Astal Laboratories financially stable compared to its competitors?
Astal Laboratories seems to be less financially stable compared to its competitors. Altman Z score of Astal Laboratories is 2.42 and is ranked 5 out of its 8 competitors.
Does Astal Laboratories pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Astal Laboratories latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Astal Laboratories allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Inventory, Accounts Receivable
How strong is Astal Laboratories balance sheet?
Balance sheet of Astal Laboratories is moderately strong.
Is the profitablity of Astal Laboratories improving?
Yes, profit is increasing. The profit of Astal Laboratories is ₹9.73 Crs for TTM, ₹8.93 Crs for Mar 2025 and ₹0.78 Crs for Mar 2024.
Is the debt of Astal Laboratories increasing or decreasing?
Yes, The net debt of Astal Laboratories is increasing. Latest net debt of Astal Laboratories is ₹47.78 Crs as of Mar-26. This is greater than Mar-25 when it was ₹9.81 Crs.
Is Astal Laboratories stock expensive?
Astal Laboratories is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE. Latest PE of Astal Laboratories is 32.84, while 3 year average PE is 85.4. Also latest EV/EBITDA of Astal Laboratories is 12.32 while 3yr average is 9.37.
Has the share price of Astal Laboratories grown faster than its competition?
Astal Laboratories has given lower returns compared to its competitors. Astal Laboratories has grown at ~-20.76% over the last 2yrs while peers have grown at a median rate of 13.73%
Is the promoter bullish about Astal Laboratories?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Astal Laboratories is 4.53% and last quarter promoter holding is 4.7%
Are mutual funds buying/selling Astal Laboratories?
There is Insufficient data to gauge this.